What is the ARA-290 peptide?

ARA-290 is an 11-amino-acid synthetic peptide also known as cibinetide. It was designed from a region of erythropoietin, or EPO. EPO is best known for its role in red blood cell production, but researchers also study its biological signaling in tissue response.

Researchers designed ARA-290 to investigate tissue-protective signaling associated with EPO while limiting stimulation of red blood cell production. That design goal does not establish that ARA-290 is safe or effective in patients. ARA-290 is not interchangeable with prescription EPO medicines.

Scientific papers describe a proposed “innate repair receptor” pathway involving the erythropoietin receptor and the beta-common receptor, also called CD131. Laboratory and animal studies have explored how this pathway may relate to inflammation and cellular injury. These proposed mechanisms are research questions, not proof of patient benefit.

For readers comparing peptide claims, the distinction matters: a proposed mechanism can explain why scientists study a compound. It cannot show that the compound treats a disease or improves a patient’s daily function.

What does human research show about ARA-290?

Published human studies include small trials in sarcoidosis-associated neuropathy, type 2 diabetes with neuropathic symptoms, and diabetic macular edema. These are distinct conditions and research questions. Results from one group should not be generalized to every cause of nerve pain or nerve damage.

The 2017 trial: a specific measurement, not proof of nerve restoration

The randomized, placebo-controlled phase 2b study enrolled 64 people with sarcoidosis-associated small-nerve-fiber loss and neuropathic pain. It compared placebo with three experimental dosing groups over 28 days. The primary outcome was change in corneal nerve-fiber area.

The 4 mg group had a statistically significant placebo-adjusted change in that measurement: 697 μm², with a 95% confidence interval of 159 to 1,236 and p = 0.012. The 1 mg and 8 mg comparisons were not statistically significant. Researchers also reported a change in a skin nerve-fiber marker in the 4 mg group.

These findings support further study of selected measurements in a particular patient population. They do not prove that ARA-290 restores normal sensation, resolves neuropathy, or produces lasting improvement in everyday function.

Pain is a separate outcome. Pain improved across the study groups. In the moderate-to-severe pain subgroup, the placebo-adjusted comparison for the 4 mg group was not statistically significant (p = 0.157). The study therefore did not conclusively demonstrate pain relief beyond placebo.

What conditions has ARA-290 been studied for?

The main cluster of human research concerns sarcoidosis-associated small-fiber neuropathy. Other small studies explored type 2 diabetes with neuropathic symptoms and diabetic macular edema. These studies do not prove that ARA-290 treats diabetic neuropathy generally, chronic pain, autoimmune disease, or nerve damage from other causes.

The 2015 type 2 diabetes study reported exploratory changes in symptom and metabolic measures. A separate 2020 study examined diabetic macular edema, an eye complication of diabetes. In that small study, average visual-acuity results did not improve. A study of one complication cannot establish that a peptide treats diabetes or a different complication.

When evaluating an online ARA-290 claim, check whether it comes from a human trial, animal model, or laboratory experiment. Then look at the study population, participant count, duration, comparator group, and outcome. A change in a biomarker or imaging measure can be useful for research. It does not automatically mean patients feel better or maintain functional improvement.

Is ARA-290 FDA-approved or available as a treatment?

No. ARA-290, or cibinetide, is not an FDA-approved drug for neuropathy, pain, inflammation, diabetes, or another condition. It has not been established as a standard clinical treatment.

In FDA’s current document for bulk drug substances nominated for use in compounding under section 503A, cibinetide (ARA-290) is listed in Category 3. FDA describes Category 3 substances as nominations submitted without adequate supporting information for FDA evaluation. This status is not approval, evidence of effectiveness, or permission to market a product as a treatment.

FDA states that Category 3 substances are not eligible for the interim policy that applies to Category 1 substances. Compounding rules depend on specific statutory and regulatory conditions and may change. Patients and clinicians should consult the latest FDA materials for current information.

An online listing, research paper, or “research use” label does not establish that a product is FDA-approved, sterile, correctly identified, accurately dosed, or suitable for human use. Do not use online instructions to obtain or inject an investigational product.

What is known about ARA-290 safety?

Some small trials did not identify major short-term safety signals during their limited observation periods. That does not establish long-term safety. Small studies cannot reliably identify uncommon adverse events, delayed effects, or risks associated with repeated exposure.

Available research cannot answer every safety question for people with cancer, significant organ disease, complex autoimmune conditions, pregnancy, or multiple medications. An individual’s health history and current care matter. This page does not recommend taking or injecting ARA-290.

Products sold online as research chemicals raise separate quality concerns. Seller claims alone do not verify identity, purity, concentration, sterility, storage, or suitability for use in people. A certificate supplied by a seller is not, by itself, proof that an injectable product is safe for human use.

Clinical context for Stamford, Connecticut

Numbness, tingling, burning sensations, altered temperature sensation, weakness, and balance changes can have many possible causes. Appropriate evaluation depends on symptoms, medical history, medications, and other clinical factors. Reading about ARA-290 cannot diagnose neuropathy or determine whether an investigational peptide is appropriate.

Optimal Health Medical is located at 111 High Ridge Road in Stamford, Connecticut. People seeking an evaluation can review the practice’s pain treatment information or contact the office with general questions. This is an invitation to discuss symptoms and care options, not an offer of ARA-290.

Contact Optimal Health Medical or call 203-348-8805.

Frequently asked questions about the ARA-290 peptide